New oral vaccine aims to boost immune attack on aggressive breast cancer
NCT ID NCT06631092
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a personalized oral DNA vaccine called NECVAX-NEO1 in 28 people with triple-negative breast cancer. The vaccine is given alongside standard chemotherapy and an immunotherapy drug before and after surgery. The goal is to see if it is safe and helps the immune system target the cancer more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized oral DNA cancer vaccine (NECVAX-NEO1)
What this could lead to
If successful, this could lead to a new add-on treatment that helps the immune system better fight triple-negative breast cancer, potentially improving outcomes when combined with standard therapy.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply broadly. The vaccine is personalized, which is complex and may not work for everyone. Side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Center for Tumor Diseases Heidelberg
RECRUITINGHeidelberg, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Clinic Erlangen
RECRUITINGErlangen, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••